GI Innovation, Inc. (KOSDAQ:358570)

South Korea flag South Korea · Delayed Price · Currency is KRW
18,180
+100 (0.55%)
Jun 5, 2025, 3:30 PM KST
88.49%
Market Cap 1.12T
Revenue n/a
Net Income n/a
Shares Out 61.61M
EPS n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 742,260
Average Volume 1,022,969
Open 18,080
Previous Close 18,080
Day's Range 17,640 - 18,620
52-Week Range 6,348 - 19,450
Beta 0.75
RSI 59.39
Earnings Date n/a

About GI Innovation

GI Innovation, Inc., a bio-venture company, engages in the research and development of protein new drugs. The company is developing GI-101, an immune anticancer drug with novel dual fusion protein in Phase I/II clinical trial; and GI-301, an IgE-mediated allergy treatment designed as a fusion protein that is in Phase I clinical trial. It is also developing GI-10N, an immuno-oncology drug; GI-30N, a drug for allergic and fibrotic diseases; and GI-20N, a drug for metabolic diseases. The company was founded in 2017 and is based in Seoul, South Kor... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 358570
Full Company Profile

News

There is no news available yet.